Please login (Members) to view content or
(Nonmembers) this article.
No votes yet
Oncology Update

Oncology Update

Diane M. Otte
ONF 2012, 39(3), 317-318 DOI: 10.1188/12.ONF.317-318

The U.S. Food and Drug Administration (FDA) has approved oral vismodegib (Erivedge™) for the treatment of adult patients with locally advanced basal cell carcinoma who are not candidates for surgery or radiation and for those with metastatic disease. The drug initially was tested at Scottsdale Healthcare in Arizona.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or